SpyGlass Pharma Inc. has developed an intraocular lens (IOL) capable of continuously delivering drugs to eyes for up to three ...

ZUG, Switzerland, Nov. 13, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis’ ...

Topical medications remain the cornerstone ... of preservatives used in the medications and the total number of all eye drops used by the patient throughout the day. Owing to the potential adverse ...

Patients taking mirvetuximab should be monitored regularly by an eye-care provider, Vingopoulos said. “The recommendation ...

Company to host an investor conference call and webcast at 4:30pm EDTNEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: EYEN), an ophthalmic technology company developing and commercializing ...

Oculis has multiple late-stage programs and catalysts. Click here to find out why I think OCS stock looks attractive.

Robert W. Baird analyst Colleen M. Kusy maintained a Buy rating on Oculis Holding (OCS – Research Report) on November 7 and set a price ...

Advanced Phase 3 CHAPERONE study of MicroPine as a treatment of pediatric progressive myopia with preparations for interim analysis this ...

Among the 422 eyes examined in the study, 94 had received no previous atropine treatment, while 328 had received between two ...

After a major recall in January of 2023, public mistrust for eye drops has caused patients to seek information regarding other DED therapies.

Harrow Inc. experienced a brief 20% stock drop in October but quickly recovered, showing resilience despite recent revenue channel underperformance. Read more here.